CTE likely begins during years of active exposure to repetitive head impacts, but symptoms typically don’t appear until about 15 years after that exposure ends. This long gap between cause and effect is one of the reasons CTE remains so difficult to detect and study. The disease can only be confirmed after death through examination of brain tissue, so pinpointing exactly when the process starts in any individual is still impossible.
The Biological Process Starts Earlier Than Symptoms
The earliest sign of CTE in brain tissue is the buildup of a toxic form of a protein called tau around small blood vessels deep in the folds of the brain’s outer layer, most often in the frontal cortex. In Stage I, the mildest form, just one or two clusters of this abnormal protein are visible under a microscope. Brain donors at this stage had an average age of about 39, and many were under 40 at death. That means the biological machinery of CTE was already running in their 20s or 30s, years before it would have caused noticeable problems.
What actually triggers that first deposit of abnormal tau remains unclear. Researchers know it’s tied to repeated head impacts, but the precise cellular event that kicks off the process hasn’t been identified. Some older former football players have been found with only Stage I or Stage II pathology decades after retiring, which suggests the disease doesn’t progress at the same rate in everyone. In some people, it may smolder at a low level for years without advancing.
Years of Hits Matter More Than Concussions
One of the most important findings in CTE research is that the total number of years spent absorbing head impacts, not the number of diagnosed concussions, is the strongest predictor of how severe the brain changes become. About 16% of confirmed CTE cases had no documented history of concussion at all. The everyday, smaller hits that don’t cause obvious symptoms (subconcussive impacts) appear to be the primary driver of the disease.
Research on former high school and college football players has identified rough thresholds for when cumulative head impacts begin to raise the risk of later-life problems. For depression and executive function difficulties, that threshold was approximately 1,800 total impacts over a career. For cognitive impairment measured by testing, the threshold was higher, around 7,250 impacts. To put that in context, the average football player in the study absorbed about 545 impacts per season. After crossing a baseline threshold, each additional 1,000 impacts (roughly two more seasons of play) meaningfully increased the risk of impairment.
When Symptoms Actually Appear
Clinical symptoms of CTE typically emerge after a latency period of about 15 years following the end of repetitive head impact exposure. But the type of symptoms that show up first varies significantly from person to person, and that variation follows a pattern linked to age.
A study of 33 people with confirmed CTE found two distinct groups. The first group developed mood and behavioral symptoms first: explosive anger, aggression, impulsivity, and depression. These individuals showed problems at an average age of 35. The second group developed cognitive symptoms first: memory loss, difficulty with planning and decision-making, and problems with attention. This group didn’t show symptoms until an average age of 59. Both groups eventually developed overlapping problems, but the initial presentation and timing were strikingly different.
This means a former athlete in their mid-30s experiencing personality changes and a former athlete in their late 50s struggling with memory could both be experiencing the early stages of CTE, just through different pathways.
How CTE Progresses Through Four Stages
Researchers use a four-stage system to describe the severity of CTE based on how much abnormal tau has spread through the brain.
- Stage I: One or two small clusters of abnormal protein around blood vessels in the frontal cortex. Average age at death for donors at this stage was about 39. Most people at this stage have few or no symptoms.
- Stage II: Three or more clusters spread across multiple brain regions, with damage extending into deeper structures involved in mood and arousal. Average age at death was about 55.
- Stage III: Large, merging patches of damaged tissue across the brain’s surface and into the memory centers, including the hippocampus and amygdala. Visible brain shrinkage and enlarged fluid-filled spaces begin to appear. Average age at death was about 66.
- Stage IV: The most severe form, with widespread damage throughout the brain.
These stages represent snapshots at the time of death, not a strict timeline every person follows. Some individuals progress quickly, while others remain at early stages for decades.
Genetics Can Influence Timing and Severity
Not everyone with the same exposure to head impacts develops the same degree of CTE, and genetics appear to play a role. Carrying a variant of the APOE gene (the ε4 version, the same gene variant linked to Alzheimer’s risk) was associated with more severe CTE pathology and a greater burden of abnormal tau in the frontal lobe. This association was significant among brain donors older than 65, with carriers roughly 2.3 times more likely to have advanced-stage CTE compared to non-carriers of the same age with similar exposure histories.
This doesn’t mean the gene variant causes CTE on its own. It appears to amplify the damage from repetitive head impacts, potentially accelerating progression in later life.
No Way to Diagnose It in Living Patients Yet
As of 2025, CTE can only be confirmed by examining brain tissue after death. There is no blood test, brain scan, or clinical exam that can definitively diagnose it in a living person. This is the central obstacle to understanding exactly when the disease begins in any individual.
That may be changing. The National Institutes of Health recently awarded $15 million to a Boston University-led effort to develop methods for diagnosing CTE during life. The study is enrolling participants across five research centers for neurological exams, cognitive testing, specialized brain imaging (including tau PET scans that can detect abnormal protein deposits), and blood draws to identify biological markers. If successful, this research could eventually make it possible to detect CTE years before symptoms become severe, fundamentally changing how early the disease can be identified and tracked.